RecruitingNCT03578185
Genomic Analysis to Identify a Predictive Biomarker for Immunotherapy
Sponsor
Se-Hoon Lee
Enrollment
800 participants
Start Date
Apr 11, 2018
Study Type
OBSERVATIONAL
Conditions
Summary
This study is designed to identify the predictive biomarker for immunotherapy using patient samples (tumor tissue, blood, fecal material) who treated with immune checkpoint inhibitor.
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- aged above or equal to 18
- Histologically confirmed lung cancer patients
- Patient treated with immune checkpoint inhibitor
- Exculsion Criteria:
- NA
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03578185
Related Trials
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
NCT046786483 locations
Virtual Agent Feasibility in Oncology Patients (NTT Data)
NCT066820131 location
Empathic Communication Skills (ECS) Training
NCT0545684112 locations
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT0661828763 locations
Study of Novel Treatment Combinations in Patients With Lung Cancer
NCT05633667100 locations